Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis
- 596 Downloads
Hypertrophic pachymeningitis (HP) is an important neurologic complication of granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis). The aim of this study is to investigate the clinical features, radiological findings, and diagnostic pitfalls of GPA-related HP. A retrospective chart review was performed to screen patients diagnosed with GPA at Samsung Medical Center between 1997 and 2016. Neurologic manifestation, laboratory findings, neuroimaging data, and clinical course were evaluated in all patients. Characteristics of patients with HP were compared to those of patients without HP. Sixty-five patients with GPA were identified. Twenty-five of these patients had central nervous system involvement. HP (N = 9, 36%) was the second most common radiologic finding. Other neurologic findings included stroke (N = 7, 28%) and granulomatous disease (N = 10, 40%). Patients with HP had lower incidences of systemic manifestations (N = 2, 22.2% vs. N = 38, 67.9%, p = 0.013 in the lung and N = 1, 11.1% vs. N = 28, 50.0%, p = 0.030 in the kidney) than those without HP. Six patients with GPA-related HP were MPO-ANCA positive (66.7%) and two had PR3-ANCA (22.2%). Most of the patients with HP presented with headache (N = 8, 88.9%) at a rate that is similar to those of primary headache disorders (migraine, tension-type, and stabbing) and other secondary headache disorders (postural type and meningitis). Patients with HP rarely had neurologic deficits (N = 3, 37.5%). Different clinical or radiologic features may be observed in GPA-related HP. Early recognition and accurate diagnosis of GPA-related HP are needed in addition to neuroimaging findings.
KeywordsGranulomatosis with polyangiitis (GPA) Wegener’s granulomatosis Hypertrophic pachymeningitis (HP) Central nervous system (CNS) Neurologic manifestations Cerebral vasculitis Antineutrophil cytoplasmic antibody (ANCA)
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
The manuscript does not contain clinical studies or patient data.
- 1.Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11. doi: 10.1002/art.37715 CrossRefPubMedGoogle Scholar
- 2.De Luna G, Terrier B, Kaminsky P, Quellec AL, Maurier F, Solans R, Godmer P, Costedoat-Chalumeau N, Seror R, Charles P, Cohen P, Puechal X, Mouthon L, Guillevin L (2015) Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology (Oxford, England) 54 (3):424–432. doi:10.1093/rheumatology/keu336Google Scholar
- 8.Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, Heller M, Gross WL (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43(5):1021–1032. doi: 10.1002/1529-0131(200005)43:5<1021:aid-anr10>3.0.co;2-j CrossRefPubMedGoogle Scholar
- 19.Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317. doi: 10.1136/ard.2008.088096 CrossRefPubMedGoogle Scholar
- 20.Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. doi: 10.1056/NEJMoa0909905 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, Csernok E, Moosig F, Schinke S, Reinhold-Keller E (2010) Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69(11):1934–1939. doi: 10.1136/ard.2010.130203 CrossRefPubMedGoogle Scholar
- 24.Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestations as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 19(5):541–549PubMedGoogle Scholar
- 28.Nagahori T, Nishijima M, Takaku A (1993) Histological study of the outer membrane of chronic subdural hematoma: possible mechanism for expansion of hematoma cavity. No shinkei geka Neurol Surg 21(8):697–701Google Scholar
- 31.Yokoseki A, Saji E, Arakawa M, Kosaka T, Hokari M, Toyoshima Y, Okamoto K, Takeda S, Sanpei K, Kikuchi H, Hirohata S, Akazawa K, Kakita A, Takahashi H, Nishizawa M, Kawachi I (2014) Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137(Pt 2):520–536. doi: 10.1093/brain/awt314 CrossRefPubMedGoogle Scholar
- 33.Csernok E, Trabandt A, Muller A, Wang GC, Moosig F, Paulsen J, Schnabel A, Gross WL (1999) Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42(4):742–750. doi: 10.1002/1529-0131(199904)42:4<742:aid-anr18>3.0.co;2-i CrossRefPubMedGoogle Scholar